Streetbeat News

Analyst Ratings

CCS

Wedbush analyst Jay McCanless has reiterated a Neutral rating on Century Communities (NYSE:CCS) and maintained a $92 price target.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 1:43 pm

NYXH

Stifel analyst Jonathan Block has maintained a Buy rating on Nyxoah (NASDAQ:NYXH) and doubled the price target from $10 to $20, indicating a positive outlook on the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 1:42 pm

SFIX

Wedbush analyst Tom Nikic has maintained a Neutral rating on Stitch Fix (NASDAQ:SFIX) and lowered the price target from $4 to $3.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 1:41 pm

HAYW

Stifel analyst W. Andrew Carter maintains a Hold rating on Hayward Holdings (NYSE:HAYW) and raises the price target from $13.5 to $14.5.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 1:39 pm

TDUP

Wedbush analyst Tom Nikic has reiterated an Outperform rating on ThredUp (NASDAQ:TDUP) and maintained a $4 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 1:39 pm

SFIX

Stitch Fix, Inc. (NASDAQ:SFIX) reported Q2 financial results below expectations and provided a weak revenue forecast for FY24, leading analysts to cut their price targets. The company reported a quarterly loss of 30 cents per share, missing the consensus estimate of a 20-cent loss, and sales of $330.4 million, below the expected $330.85 million. The forecast for Q3 revenue is between $300 million and $310 million, against an estimate of $322.29 million, with FY24 revenue expected to be between $1.29 billion and $1.32 billion, below the consensus of $1.35 billion. Despite this, SFIX shares rose 2.2% to close at $3.28.

Portfolio Pulse from Avi Kapoor

March 05, 2024 | 1:36 pm

LEN

Wedbush analyst Jay McCanless has reiterated a Neutral rating on Lennar (LEN) and maintained a $130 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 1:36 pm

ATXS

Wedbush analyst Laura Chico reiterates an Outperform rating on Astria Therapeutics (NASDAQ:ATXS) and maintains a $17 price target.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 1:34 pm